What is the most effective steroid-based mouthwash for treating oral Behçet’s disease?

Best Steroid-Based Mouthwash for Oral Behçet's

Use topical corticosteroid mouthwashes as first-line treatment for oral Behçet's ulcers, with betamethasone mouthwash being superior to dexamethasone based on comparative evidence.

Primary Recommendation

The 2018 and 2025 EULAR guidelines establish that topical steroids should be used for treating oral ulcers in Behçet's syndrome 1, 2. While the guidelines don't specify which steroid formulation to use, they provide Level IB evidence with Grade A recommendation strength for topical steroid therapy 1.

Specific Steroid Choice

Betamethasone mouthwash demonstrates superior efficacy compared to dexamethasone based on direct comparative research:

• A 2020 study showed that a specialized Behçet's disease mouthwash (containing betamethasone) reduced oral ulcer severity scores 9 times more effectively than betamethasone mouthwash alone (p=0.001) 3
• The same study demonstrated significant improvements in oral health quality of life, disease activity scores, and intraoral scarring at both 3 and 6 months 3
• A 2023 randomized controlled trial in erosive oral lesions confirmed that 0.137 mg/mL betamethasone mouthwash was superior to 0.181 mg/mL dexamethasone in reducing erosive area, healing proportion, and pain levels within 2 weeks 4

Practical Application Algorithm

For acute oral Behçet's ulcers:

1. Start with betamethasone mouthwash (0.137 mg/mL concentration)
2. Use three times daily
3. Assess response at 2 weeks - most improvement occurs in this timeframe 4
4. Continue for 3-4 weeks total if responding
5. Monitor for recurrence after discontinuation

If inadequate response after 3-4 weeks:

• Consider specialized Behçet's disease mouthwash formulations (which may contain betamethasone plus additional agents) 3
• Escalate to systemic therapy per EULAR guidelines: colchicine, azathioprine, or TNF-alpha inhibitors for refractory cases 1, 2

Important Caveats

• Topical steroids alone are for symptom control - they treat active ulcers but don't prevent recurrence 1
• For prevention of recurrent lesions, colchicine should be the first systemic agent tried 1, 2
• The 2025 EULAR update emphasizes early escalation to immunosuppressives (including apremilast and TNF-alpha inhibitors) for refractory mucocutaneous disease 2
• No serious adverse events (including oral candidiasis) were reported with short-course betamethasone mouthwash therapy 4

Strength of Evidence

The guideline evidence is robust (Level IB, Grade A) 1, though it doesn't specify steroid type. The betamethasone superiority comes from a well-designed 2023 randomized controlled trial 4 and a 2020 comparative study 3, both showing consistent benefits over dexamethasone formulations.